{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:52:34Z","timestamp":1778230354907,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.clml.2012.04.002","type":"journal-article","created":{"date-parts":[[2012,5,24]],"date-time":"2012-05-24T12:13:48Z","timestamp":1337861628000},"page":"223-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Adherence to BCR-ABL Inhibitors: Issues for CML Therapy"],"prefix":"10.1016","volume":"12","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.04.002_bib2","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group","volume":"89","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2012.04.002_bib3","series-title":"Gleevec (imatinib) [prescribing information]","year":"2010"},{"key":"10.1016\/j.clml.2012.04.002_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.04.002_bib5","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.04.002_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2012.04.002_bib9","series-title":"Sprycel (dasatinib) [package insert]","year":"2011"},{"key":"10.1016\/j.clml.2012.04.002_bib10","series-title":"Tasigna (nilotinib) [prescribing information]","year":"2011"},{"key":"10.1016\/j.clml.2012.04.002_bib11","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.04.002_bib12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.04.002_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.04.002_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2012.04.002_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1016\/j.clml.2012.04.002_bib16","first-page":"S1","article-title":"NCCN Task Force report: oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clml.2012.04.002_bib17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2012.04.002_bib18","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clml.2012.04.002_bib19","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2012.04.002_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000100444","article-title":"Adherence to endocrine therapy for breast cancer","volume":"71","author":"Chlebowski","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2012.04.002_bib21","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","article-title":"Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients","volume":"28","author":"Hershman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.04.002_bib22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.04.002_bib23","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6604758","article-title":"Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer","volume":"99","author":"McCowan","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2012.04.002_bib24","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.04.002_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.04.002_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2012.04.002_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"Suppl","key":"10.1016\/j.clml.2012.04.002_bib28","first-page":"330S","article-title":"Prescription compliance and persistence in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM)","volume":"24","author":"Tsang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.04.002_bib29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.V114.22.2209.2209","article-title":"Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia [abstract]","volume":"114","author":"St Charles","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.04.002_bib30","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.04.002_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2010.08245.x","article-title":"Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia","volume":"150","author":"Santos","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.04.002_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1188\/09.CJON.329-335","article-title":"Practical management for dasatinib for maximum patient benefit","volume":"13","author":"Galinsky","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clml.2012.04.002_bib33","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.04.002_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2796.2008.02010.x","article-title":"Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance","volume":"264","author":"Boonen","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.clml.2012.04.002_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00002512-200724010-00003","article-title":"Patient adherence to osteoporosis medications: problems, consequences and management strategies","volume":"24","author":"Papaioannou","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clml.2012.04.002_bib36","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1001\/jama.288.22.2868","article-title":"Interventions to enhance patient adherence to medication prescriptions","volume":"288","author":"McDonald","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2012.04.002_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"25","author":"Jabbour","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.04.002_bib38","first-page":"1405","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial","volume":"116","author":"Saglio","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:22Z","timestamp":1761870142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012000560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S2152265012000560"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.04.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to BCR-ABL Inhibitors: Issues for CML Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}